4.8 Article

Synthetic Lethality through Combined Notch-Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer

期刊

CANCER RESEARCH
卷 70, 期 13, 页码 5465-5474

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-0173

关键词

-

类别

资金

  1. Flight Attendant Medical Research Institute
  2. Susan G. Komen for the Cure
  3. Department of Defense [W81XWH-08-1-0178]

向作者/读者索取更多资源

Basal-like breast cancers (BLBC) are highly aggressive, yet selective therapies targeting the specific oncoproteins driving these tumors have not been developed. These cancers frequently express epidermal growth factor receptor (EGFR), with resistance to its inhibition being well documented, albeit poorly understood. Notch pathway activation is also common in this breast cancer subtype and can be suppressed by gamma-secretase inhibitors, which effectively block receptor cleavage and activation. Herein, we show that although inhibition of either EGFR or Notch signaling alone is insufficient to suppress basal-like breast tumor cell survival and proliferation, simultaneous inhibition uncovers a synthetic lethal relationship between these two oncogenic pathways. This lethality is due in part to significant decreases in AKT activation caused by combined EGFR and Notch inhibition. Expression of the activated form of Notch1 restores AKT activity and enables cells to overcome cell death after dual-pathway blockade. Combined pathway inhibition is also dramatically more effective at suppressing tumor growth in mice than blocking EGFR or Notch signaling alone. Thus, we show that Notch pathway activation contributes to resistance to EGFR inhibition, and provide a novel treatment strategy for BLBCs. Cancer Res; 70(13); 5465-74. (C)2010 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据